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Abstract
Introduction
The farnesoid X receptor (FXR) is abundantly expressed in the ileum, where it exerts an
enteroprotective role as a key regulator of intestinal innate immunity and homeostasis, as
shown in pre-clinical models of inflammatory bowel disease. Since intestinal ischemia reper-
fusion injury (IRI) is characterized by hyperpermeability, bacterial translocation and inflam-
mation, we aimed to investigate, for the first time, if the FXR-agonist obeticholic acid (OCA)
could attenuate intestinal ischemia reperfusion injury.
Material and Methods
In a validated rat model of intestinal IRI (laparotomy + temporary mesenteric artery clamp-
ing), 3 conditions were tested (n = 16/group): laparotomy only (sham group); ischemia
60min+ reperfusion 60min + vehicle pretreatment (IR group); ischemia 60min + reperfusion
60min + OCA pretreatment (IR+OCA group). Vehicle or OCA (INT-747, 2*30mg/kg) was
administered by gavage 24h and 4h prior to IRI. The following end-points were analyzed: 7-
day survival; biomarkers of enterocyte viability (L-lactate, I-FABP); histology (morphologic
injury to villi/crypts and villus length); intestinal permeability (Ussing chamber); endotoxin
translocation (Lipopolysaccharide assay); cytokines (IL-6, IL-1-β, TNFα, IFN-γ IL-10, IL-13);
apoptosis (cleaved caspase-3); and autophagy (LC3, p62).
Results
It was found that intestinal IRI was associated with high mortality (90%); loss of intestinal
integrity (structurally and functionally); increased endotoxin translocation and pro-inflamma-
tory cytokine production; and inhibition of autophagy. Conversely, OCA-pretreatment
improved 7-day survival up to 50% which was associated with prevention of epithelial injury,
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preserved intestinal architecture and permeability. Additionally, FXR-agonism led to
decreased pro-inflammatory cytokine release and alleviated autophagy inhibition.
Conclusion
Pretreatment with OCA, an FXR-agonist, improves survival in a rodent model of intestinal
IRI, preserves the gut barrier function and suppresses inflammation. These results turn FXR
into a promising target for various conditions associated with intestinal ischemia.
Introduction
Intestinal ischemia is a common (1/1000 hospital admissions) and life-threatening condition,
occurring in a wide range of conditions [1]. Due to delayed diagnosis and lack of efficient
treatment, the impact is detrimental with an in-hospital mortality up to 80% [1]. Moreover,
when blood flow can be restored to the ischemic organ (reperfusion), it exacerbates the delete-
rious effect of ischemia, enhancing oxidative stress, activating innate immunity, inflammation
and cell death. This phenomenon is usually referred to as ´ischemia-reperfusion injury´ (IRI)
[2,3]. It also represents a huge obstacle in the setting of intestinal transplantation, in which IRI
accelerates the immune response towards the graft, resulting in high risk for allograft rejection
[4].
Intestinal IRI is particularly detrimental -compared to other organs- as damage to the
mucosal barrier results in bacterial translocation, ultimately leading to sepsis, multiple organ
failure and death [5,6].
The intestinal epithelial cell is increasingly recognized as an important mediator of inflam-
mation as the mucosal lining is continuously exposed to environmental factors and bacteria
and as such, actively contributes to the antimicrobial host defense and maintenance of mucosal
homeostasis [7]. Animal and clinical research in recent years has shown the importance of the
bile acid responsive nuclear transcription factor farnesoid X receptor (FXR) in regulating
intestinal innate immunity and maintaining barrier homeostasis [8–10]. FXR, in essence a key
regulator of bile acid metabolism, is most abundantly expressed in the tissues commonly
exposed to bile acids, including the liver and intestine. Along the gastro-intestinal tract, higher
FXR levels can be found in the ileal epithelium, the main site of intestinal bile acid absorption
[11,12]. The FXR system is of interest from the perspective of IRI because of its anti-inflamma-
tory and regenerative properties that are well known to protect gut barrier integrity [9,13].
More specifically, in “loss of function”-experiments with FXR-knockout mice, animals devel-
oped an inflammatory bowel disease (IBD)-like phenotype with increased intestinal inflamma-
tion and permeability, and eventually bacterial translocation [13]. Conversely, in “gain of
function”-experiments, obeticholic acid (OCA), a first-in class highly selective and potent
FXR-agonist, preserved intestinal barrier function by downregulating pro-inflammatory cyto-
kine production (via NF-κB inhibition) and reducing permeability in both a model of chemi-
cal colitis and bile-duct ligated cirrhosis [8,9]. Recently, FXR has also been found to be a
regulator of autophagy, an intracellular catabolic pathway crucial in maintaining cellular
homeostasis and thereby regulating cell life versus death [14,15].
Since intestinal IRI engages in most of these pathophysiological pathways, we hypothesized
that FXR might be dysfunctional in IRI and that boosting the FXR-pathway may attenuate IRI
and its detrimental consequences. We therefore investigated whether OCA could overcome
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loss of gut barrier function, suppress inflammation and prevent death in a rodent model of
intestinal IRI.
Material and Methods
Animal model
Male Sprague Dawley rats (n = 48) weighing 275-325g (Janvier Labs, Saint Berthevin Cedex,
France) were housed in the KULeuven animal facility under specific pathogen-free conditions.
Institutional animal research oversight committee (KULeuven ethische commissie) approval
—following the EU directive for animal experiments—was obtained under the number (P141-
2012). Animals were anaesthetized by an intraperitoneally administered mix of ketamin
(1100mg/kg, Anesketin, Eurovet, the Netherlands) and xylazin (110mg/kg, Xyl-M 2%, Van
Miert&Dams Chemie, Belgium). In accordance to animal welfare, rats were monitored at least
3 times daily and buprenorphine (Vetergesic) was used for analgesia during the first 2 days fol-
lowing the experiments. A morbidity score (including weight changes: 3 points, behavior: 3
points and stool presence: 1 point) with a maximum of 7 was used. If a score was higher than
3, the protocol included euthanasia by overdose of pentobarbital (Nembutal) after anesthesia
induction. None of the rats included had to be euthanized.
Intestinal IRI was induced after median laparotomy by isolated temporary clamping of the
superior mesenteric artery. This is a well-validated model of intestinal IRI and very often used
in literature due to its ´minimal-touch´ technique and clinical significance. Rats were ran-
domly divided into three groups (n = 6/group): i/ laparotomy only, no ischemia (Sham group);
ii/ Ischemia 60 min + Reperfusion 60 min (IR) + pretreatment with vehicle (IR group); iii/
Ischemia 60 min + Reperfusion 60 min + pretreatment with OCA (IR + OCA group). 60 min-
utes of ischemia were chosen since this time period provokes far more deleterious effects of
intestinal ischemia than 30 or 45 minutes and keeps the animal alive during the reperfusion
period. Vehicle or OCA (INT-747, 230mg/kg, provided by Intercept Pharmaceuticals Inc.,
NY, USA) was administered by gavage 24h and 4h prior to IRI. Time points were chosen for
pharmacodynamic reasons and adapted from previous experiments [9,16].
For survival analysis, 10 additional animals were included per group and observed on a
daily basis for 7 days. Autopsy was performed in those that died during follow-up. At the end
of the experiment (after 60 min or 7 days of reperfusion), all animals were sacrificed by exsan-
guination under anaesthesia, followed by blood and intestinal tissue collection.
Blood and tissue sampling
Heparinized blood samples were collected after puncture of the aorta, spun at 3500xg for 10
min, frozen in liquid nitrogen and stored at -80˚C. Five ileal samples of 1 cm were collected at
10 cm from the ileo-caecal valve, corresponding in the IR-groups to clearly macroscopically
damaged tissue. One ileal tissue sample was kept viable in oxygenated medium for immediate
analysis in an Ussing chamber for permeability assay, one was placed in 10% neutral-buffered
formalin for histological evaluation and three others were snap-frozen in liquid nitrogen and
stored at -80˚C for Western blot (WB) and quantitative reverse-transcription polymerase
chain reaction (qRT-PCR) analysis.
Biomarkers of ischemia reperfusion injury
Plasmatic L-lactate release was analyzed by a bloodgas analyzer (ABL-815, Radiometer, Den-
mark), lactate dehydrogenase (LDH) (Cobas, Roche, Basel, Switzerland) and intestinal fatty
acid binding protein (I-FABP) -a marker of enterocyte damage- by WB [17,18].
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Histological evaluation
Formalin-fixed tissue samples were embedded in paraffin and cut into 5 μm sections and
stained with haematoxylin and eosin (HE). The samples were evaluated by an experienced
pathologist (GDH) blinded to treatment allocation. Four fields per section were analysed for
IRI-related damage and quantified by the Park-Chiu scoring system, which grades progression
of morphologic injury to villi and crypts in 8 grades [19,20]. Villus length -defined as the dis-
tance between the mouth of the crypts and the tip of the villi—was measured in 4 different
fields per tissue section, and the average was calculated to avoid the potential impact of patchy
necrosis.
Assessment of intestinal permeability by measurement of transepithelial
electrical resistance and dextran flux
To assess the impact of IRI on epithelial integrity, full thickness ileal tissue was mounted
blindly in triplicate in Ussing chambers with a 9.60 mm2 area of tissue exposed, as previously
described [9]. In brief, mucosal and serosal sides were exposed to 10 mM mannitol and 10
mM glucose in Krebs-Ringer bicarbonate buffers respectively, which were kept at 37˚C and
carboganated with 95%/5% O2/CO2. Trans-epithelial electrical resistance (TEER) was mea-
sured by averaging 60 min of measurement after an initial 30 min stabilization period. Trans-
epithelial paracellular passage of fluorescein isothiocyanate (FITC)-labelled 20 kiloDalton
(kDa) dextran (Sigma-Aldrich, Belgium) from the mucosal to the serosal side was alternatively
examined and determined by measuring fluorescence levels by an AscentTM Fluoroskan
microplate fluorometer (Thermo-Scientific, MA, USA) in the serosal buffer samples, taken
every 30 min after adding 1 mg/ml to the mucosal buffer.
In our particular setting of intestinal IRI, leading to diminished/denudated mucosal surface
area (as observed histologically), TEER and dextran-flux were corrected by multiplying TEER
or dextran passage with its corresponding villus length divided by the average villus length of
the sham group.
Assessment of bacterial translocation
Plasma endotoxin levels were measured by the colorimetric Limulus Amebocyte Lysate (LAL
QCL1000) test, per manufacturer´s instruction (Lonza, Switzerland).
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
The relative expression of pro-inflammatory cytokines (Interleukin (IL)-6, IL-1-β, tumor
necrosis factor (TNF)-α, interferon (IFN)-γ), anti-inflammatory cytokines (IL-10 and IL-13),
autophagic proteins (LC3, p62), FXR and small heterodimeric partner (SHP) were determined
by qRT-PCR. Tissue was homogenized in TRIzol reagent (Life Technologies, CA, USA) and
total ribonucleic acid (RNA) was extracted using the RNeasy isolation kit (Qiagen, MD, USA)
according to the manufacturer’s instructions. c-DNA was synthesized from 200ng RNA using
M-MLV transcriptase (Life-Technologies, CA, USA). Next, the real-time qPCR reaction was
performed on a LightCycler 96W (Roche, Vilvoorde, Belgium) with Taqman Fast Universal
PCR Master Mix and Taqman Gene Expression Assays (Applied Biosystems, Life Technolo-
gies, CA, USA) (IL-6 (Rn01410330_m1), IL-1-β (Rn00580432_m1), TNF-α, (Rn00562055)
IFN-γ (Rn00594078), IL-10 (Rn00563409), IL-13 (Rn00587615), LC3 (Rn02132764) and p62
(Rn00709977). For FXR and SHP, specific primers were designed using sequence data and
nucleotide BLAST software from the National Center for Biotechnology Information database
(http://www.ncbi.nlm.nih.gov/nucleotide) and were manufactured by TIB MolBiol (Berlin,
FXR Activation Limits Intestinal IRI
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Germany). (FXR: 5´-cattaacaacgcgcrcacctg-3´ and 3´-ttccttagccggcaat
cctg-5´; SHP: 5´-cttgagctgggtcccaagga-3´ and 3´-ctagctgggtaccagggc
tc-5´). A three-step amplification program was used: 95˚C for 10 min followed by 45 cycles
of amplification (95˚C for 10 sec, 60˚C for 15 sec, 72˚C for 10 sec) and finally a melting curve
program. Target messenger RNA (mRNA) expression was quantified relative to the house-
keeping gene GAPDH (Life Technologies, CA, USA) for cytokines and to Hprt1 (5´-gccaa
agtggaaaagccaagt-3´and 3´-gccacatcaacaggactcttgtag-5´) for FXR and
SHP using the -ΔΔCt method.
Western blot
Plasma samples (I-FABP) and ileal samples (apoptosis and autophagy) were used. Ileal samples
were homogenized in RIPA buffer containing 50 mM Tris/HCl, 1 mM ethylenediamine tetraa-
cetic acid, 150mM sodiumchloride, 1% IPEGAL, 1% Protease Inhibitor Cocktail (Sigma-
Aldrich), 1% Phosphatase Inhibitor Cocktail 2 and 3 (Sigma-Aldrich). Protein concentration
was measured by Bradford assay (Sigma-Aldrich, MO, USA). Samples (50 μg protein) were
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using
any kDa Mini-Protean TGX Precast Gels (Bio-Rad, CA, USA) and proteins were blotted on
polyvinylidene difluoride (PVDF) membranes using the Transblot Turbo system (Bio-Rad,
CA, USA). As loading control for the plasma samples, the membranes were incubated with
0.1% Ponceau S staining solution. The membranes were blocked for 1 hour at room tempera-
ture with PBS-Tween (0.1%) containing 5% milk powder and incubated with the primary anti-
body overnight at 4˚C. Primary antibodies include: anti-I-FABP for plasma samples (21252-
1-AP Proteintech Europe) as enterocyte damage marker, anti-cleaved caspase 3 (9664, Cell Sig-
naling Technologies, Manchester, UK) as apoptosis marker; anti-LC3 (5F10, Nanotools, Mu¨n-
chen, Germany) as autophagy marker and anti-beta-actin (A2228, Sigma-Aldrich, MO, USA)
as loading control for the tissue samples. As a key autophagy event, the conversion of protein
LC3 from LC3-I into LC3-II was analysed. Next, the membranes were incubated with the cor-
responding secondary antibody {anti-mouse or anti-rabbit IgG HRP-linked antibodies (Cell
Signaling Technologies, MA, USA)}. The proteins were detected using enhanced chemolumi-
nescence (Pierce ECL Western Blotting Substrate) and digital detection with the Chemidoc
MP system. Quantification of relative band intensity was then performed with the associated
ImageLab software (Bio-Rad, CA, USA).
Statistical analysis
Data were subjected to equal variance and normality testing (Kolmogorov-Smirnov test). All
data were expressed as mean ± standard deviation and represented in scattered plots. The line
in the middle of the box is plotted at the mean. The whiskers indicate the standard deviation.
Comparisons between multiple groups were performed with One-Way Anova and post-hoc
Bonferroni test in case of normal distribution or Kruskal-Wallis post-hoc Dunn test for non-
normal distribution. Survival analysis was performed by Kaplan-Meier (log-rank test). A p
value <0.05 was considered statistically significant (Graphpad Prism 5, San Diego, CA, USA).
Results
Pretreatment with OCA improves survival after intestinal IRI
All sham-operated rats survived for 7 days, illustrating that the operating procedure itself was
not fatal. With IRI only, 7-day survival was limited to 1 out of 10 (10%) with early death (i.e.
<24 hours) in 5 animals, as a consequence of intestinal perforation due to breakdown of the
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mucosal integrity as observed during the post-mortem autopsy. Four others died between day
2 and 5, which could be attributed to sepsis and multiple organ failure. Increasing FXR activity
pre-IRI by means of OCA gavage, increased survival up to 50%. The five rats that succumbed,
died within the first day following reperfusion (Fig 1).
Oral gavage with OCA preserves the FXR pathway in the ileum during
IRI
The ileal mRNA expression of FXR was markedly reduced in the IR group compared to the
sham group (-4.34±1.89 vs. 0.00±0.62, p<0.001) but after OCA pretreatment, FXR expression
levels maintained comparable to the sham group (-1.65±0.48 vs. 0.00±0.62; p = 0.086) (Fig 2A).
To confirm that the administered dose of OCA activated the FXR pathway in the ileum, the
expression of the FXR downstream target gene SHP was assayed in the ileum. In the OCA-pre-
treated group, SHP expression was up-regulated compared to the vehicle-pretreated (3.53±1.04
Fig 1. OCA improves 7-day survival after intestinal IRI. OCA: obeticholic acid; IRI: ischemia reperfusion
injury. n = 10/group, log-rank: p = 0.0128.
doi:10.1371/journal.pone.0169331.g001
Fig 2. OCA re-activates the FXR-SHP pathway in intestinal IRI as shown by (A) FXR mRNA expression; and (B) FXR downstream target gene SHP
expression. mRNA levels were expressed as -ΔΔCt; OCA: obeticholic acid; FXR: farnesoid X receptor; SHP: small heterodimeric partner; IRI: ischemia
reperfusion injury, mRNA: messenger ribonucleic acid. **: p<0.01; ***: p<0.001.
doi:10.1371/journal.pone.0169331.g002
FXR Activation Limits Intestinal IRI
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vs. -0.43±1.63; p<0.001) and sham group (-0.27±0.31; p<0.001), implying activation of the
downstream FXR signaling pathway upon OCA pretreatment (Fig 2B).
Pretreatment with OCA prevents plasmatic release of injury biomarkers
after IRI
After 60 min of reperfusion of the small bowel, L-lactate release was 4 times higher than in the
sham group (4.52±1.77 vs. 1.08±0.25 mmol/L; p<0.001) and LDH release was 3 times higher
than in the sham group (675.50±81.21 vs. 199.30±61.21 U/L; p<0.001). In OCA-pretreated
rats, L-lactate (2.15±0.96 mmol/L) and LDH (409.80±179.50 U/L) levels were markedly lower
in comparison to the vehicle-pretreated group (p<0.01 in both) and comparable to the sham-
operated group (Fig 3A and 3B).
The enterocyte damage marker I-FABP remained undetected in the plasma of sham rats,
while a clear appearance of I-FABP in the plasma was observed following reperfusion. Plasma
Fig 3. OCA attenuates plasmatic release of intestinal IRI marker: (A) L-lactate; (B) LDH; (C) I-FABP. OCA: obeticholic acid; I-FABP:
Intestinal fatty acid binding protein; LDH: lactate dehydrogenase; IRI: ischemia reperfusion injury; kDa: kiloDalton. *: p<0.05; **: p<0.01;
***: p<0.001.
doi:10.1371/journal.pone.0169331.g003
FXR Activation Limits Intestinal IRI
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I-FAPB levels were again reduced following OCA pretreatment (3.74±1.50 vs. 14.69±11.60;
p<0.05) (Fig 3C).
Pretreatment with OCA protects against intestinal histological damage
provoked by IRI
The impact of IRI on the intestinal wall integrity was demonstrated by the histological evalua-
tion of the ileal tissue (Fig 4A–4C). The Park-Chiu score after IRI was 5.13±0.74, which was
reduced by OCA pretreatment (2.50±1.26; p<0.001). These injury scores were also reflected
by the differences in villus length. After reperfusion, villi were damaged with a remaining
length of 48.48±7.74 μm in contrast to the OCA-pretreated group which clearly showed
remaining villus structures with a length of 88.00±7.04 μm (p<0.001). HE staining revealed
that the breakdown of the intestinal mucosa, due to IRI, was accompanied by dilated lymphat-
ics and a pronounced interstitial edema.
Fig 4. A-C OCA preserves the intestinal mucosal wall integrity in intestinal IRI as shown by (A) Park-Chiu score; (B) villus-length; and (C)
representative histological illustration for each group, Hematoxylin and Eosin staining, magnification: X200. OCA: obeticholic acid; TEER: trans-
epithelial electrical resistance; FD20: fluorescein isothiocyanate-labelled dextran 20 kiloDalton; IRI: ischemia reperfusion injury; *: p<0.05; **:
p<0.01; ***: p<0.001. D-F The protective effect of OCA on intestinal wall permeability is reflected by (D) its amelioration of TEER, (E) prevention of
FD20 leakage; and (F) prevention of endotoxin translocation after intestinal IRI. OCA: obeticholic acid; TEER: trans-epithelial electrical resistance;
FD20: fluorescein isothiocyanate-labelled dextran 20 kiloDalton; IRI: ischemia reperfusion injury; *: p<0.05; **: p<0.01; ***: p<0.001.
doi:10.1371/journal.pone.0169331.g004
FXR Activation Limits Intestinal IRI
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OCA pretreatment preserves intestinal permeability and prevents
endotoxin translocation following IRI
The histological findings were paralleled by analogous findings in terms of permeability and
endotoxin translocation (Fig 4D–4F). IRI results in higher permeability, as evidenced by a
lower TEER and higher dextran flux compared with sham (15.0.6±3.45 vs. 63.57±10.44 Ocm2;
p<0.001 and 91.63±38.30 vs. 36.17±22.49 pmol/cm2; p<0.05, respectively). In accordance,
plasma endotoxin levels were also elevated following reperfusion (0.09±0.03 vs. 0.05±0.01 U/L
in sham; p<0.05). OCA pretreatment ameliorated intestinal permeability and prevented endo-
toxin translocation.
OCA pretreatment impedes the pro-inflammatory response provoked by
IRI
With IRI, plasmatic IL-6 mRNA expression increased (2.86±0.78) compared to the sham
(-0.34±0.74). With OCA pretreatment, IL-6 levels were lower than in the IR group (1.41
±0.61; p<0.01) (Fig 5A). This alteration in inflammatory state was confirmed in the intes-
tine by the increased mRNA levels of the pro-inflammatory cytokine IL-1-β in the IR group
compared to the sham group (1.57±0.67 vs. 0±0.99; p<0.01). With OCA pretreatment, IL-1-
β expression was lower compared to the vehicle-pretreated group (-0.17±0.50 vs. 1.57±0.67;
p<0.01) (Fig 5B). Variation in TNF-α expression was relatively large, and although a trend
towards lower expression in the OCA-pretreated group could be observed, no significant
differences were found (Fig 5C). Expression of IFN-γ was lower in the OCA-pretreated
group compared to the sham group (-2.16±1.07 vs. 0±1.10; p<0.01), and IR group (-0.46
±0.89; p<0.05) (Fig 5D).
Concerning the anti-inflammatory gene expression of IL-10 and IL-13, no differences
could be observed between the different groups (Fig 5E and 5F).
OCA pretreatment alleviates IRI-related increase in apoptosis
Intestinal IRI resulted in increased apoptosis, as observed by an increase of cleaved caspase-3,
compared to the sham-operated group (1.00±0.42 vs. 0.34±0.12; p<0.01). With OCA pretreat-
ment, the difference with the sham group was alleviated (0.67±0.95 vs. 0.34±0.12; p = 0.43)
(Fig 6A).
OCA pretreatment alleviates the suppression of autophagic flux induced
by IRI
Autophagic flux was analysed based on the conversion of protein LC3 from LC3-I into LC3-II.
With IRI, elevated levels of LC3-I were found in the ileum compared to the sham group (0.99
±0.10 vs. 0.20±0.05; p<0.001). This effect was not due to increased transcription, since the
LC3 mRNA levels were not significantly reduced during IRI. Because a similar trend was not
observed for LC3-II, the accumulation of LC3-I suggests a hampered conversion from LC3-I
into LC3-II, leading to a reduced autophagic flux (Fig 6B). Interestingly, with OCA pretreat-
ment the IRI-induced accumulation of LC3-I was attenuated (0.54±0.18 vs. 0.99±0.10; p<
0.001). This OCA-mediated decrease in LC3-I on the protein level was associated with a de-
crease in LC3 mRNA transcription compared to the sham group (-0.75±0.37 vs. -0.00±0.33;
p<0.01) (Fig 6C). These findings suggest that activation of FXR can alleviate the IRI-induced
inhibition of autophagy by limiting LC3 transcription. Similar mRNA data were found for p62
gene expression which encodes a LC3-binding protein involved in cargo sequestering into
autophagic vesicles (Fig 6D).
FXR Activation Limits Intestinal IRI
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Discussion
Intestinal ischemia, both occlusive (e.g. bowel infarction, strangulation) as non-occlusive (e.g.
severe hypotension, shock), is a frequent and clinically devastating condition characterized by
high morbidity and mortality. It also remains a major obstacle to successful intestinal trans-
plantation due to the risk of eliciting the alloimmune response towards the graft. Compared to
other organs, intestinal IRI is uniquely aggressive, as damage to the mucosal barrier instigates
Fig 5. Suppressive effect of OCA on inflammation in intestinal IRI as shown by (A) mRNA expression of pro-inflammatory cytokines
IL-6; (B) IL-1-β; (C) TNF-α; and (D) IFN-γ. mRNA expression of anti-inflammatory cytokines (E) IL-10; and (F) IL-13 did not differ
between the different groups. OCA: obeticholic acid; IRI: ischemia reperfusion injury; IL: interleukin; TNF-α: tumor necrosis factor-
alpha; IFN-γ: interferon-gamma. *: p<0.05; **: p<0.01.
doi:10.1371/journal.pone.0169331.g005
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bacterial translocation, sepsis, multiple organ failure and eventually death [1,3,6]. Nevertheless,
its pathophysiology remains ill-defined.
Our findings indicate -for the first time- that a dysfunction in the intestinal FXR-signaling
plays a pivotal role as a molecular switch in intestinal IRI to drive loss of intestinal barrier
integrity with subsequent triggering of bacterial translocation, release of pro-inflammatory
cytokines and death (Fig 7). We show that this chain of acute events could be prevented, with
a clinically relevant gain in survival, by pretreatment with the FXR-ligand OCA (INT-747).
OCA, or 6-alpha-ethyl-chenodeoxycholic acid, is a semi-synthetic bile acid derivative, whose
value and safety has recently been authenticated in phase-II and -III clinical trials for non-alco-
holic fatty liver disease and primary biliary cholangitis respectively [21,22]. While early
Fig 6. A Effect of OCA on ileal apoptosis is reflected by (A) the analysis of Cleaved caspase-3 in ileal tissue lysates by means of western blot and
band intensity which was quantified in comparison to actin. The vertical double lines indicate that the lanes were taken from another part of the
same gel. OCA: obeticholic acid; IRI: ischemia reperfusion injury; kDa: kiloDalton. **: p<0.01. B-D Effect of OCA on autophagy as illustrated by its
effect on (B) LC3 at the protein level (western blot); and (C) the transcriptional level (qRT-PCR), as well as (D) p62 at the transcriptional level
(qRT-PCR). OCA: obeticholic acid; IRI: ischemia reperfusion injury; qRT-PCR: quantitative reverse-transcription polymerase chain reaction kDa:
kiloDalton. *: p<0.05; **: p<0.01; ***: p<0.001.
doi:10.1371/journal.pone.0169331.g006
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translational studies were focused on the central role of FXR as a chief regulator of bile acid
and lipid metabolism, the hepatic involvement of FXR and the beneficial effects of FXR ago-
nists on hepatic inflammation and fibrosis were subsequently illustrated in both animal mod-
els of non-alcoholic fatty liver disease and toxic cirrhosis, amongst others [23–26]. Since then,
the body of literature on FXR has rapidly expanded to extrahepatic compartments, such as vas-
culature (more specifically systemic and liver sinusoidal endothelium), lung (pulmonary arte-
rial hypertension), kidney and the immune system [16,25,27–33].
Comparably, only a relatively small number of studies assessed the function of FXR in the
intestine [8,10,13,34–37]. Recent studies revealed that FXR-knockout mice display a chronic
IBD-like phenotype with impaired intestinal mucosal integrity leading to increased intestinal
permeability and bacterial translocation from the gut [10,35,37]. Loss of intestinal epithelial
barrier function has been observed in several disorders like IBD, cirrhosis and -most extreme-
intestinal IRI [1,38,39]. Key pathophysiological players that instigate and determine the extent
of injury following this breach of barrier integrity relate to the extent of increased permeability
(with bacterial translocation) and pro-inflammatory response eventually leading to cell death
[1–4]. Since these two factors closely interact, they act as a vicious circle propagating tissue
injury and ultimately resulting in multiple organ failure [1,6]. The central role of FXR pathway
dysfunction in intestinal homeostasis (with or without bacterial translocation) has been docu-
mented in experimental models of cirrhosis and colitis [8–10,13,16], but has not been assessed
so far in the acute event of intestinal IRI.
The intestinal epithelium represents the largest and most vulnerable surface area separating
the host internal milieu from the luminal contents of the intestine [40]. It is of utmost impor-
tance to protect this intestinal barrier thereby preventing external antigens and micro-organ-
isms and bacterial products from spreading through the body [41,42]. This physical barrier
consists of enterocytes tightly connected by intracellular junctions [43]. Depending on the
level of injury, enterocytes also secrete cytokines and chemokines, which trigger the inflamma-
tory response, as a second line of defense against the luminal contents [7,44,45], resulting in
infiltration of neutrophils, macrophages and other immune cells to the site of intestinal dam-
age or inflammation [4].
Fig 7. Activation of farnesoid X receptor acts as a central molecular switch in intestinal IRI to decrease
inflammation and protect intestinal barrier integrity with subsequent prevention of bacterial
translocation. IRI: Ischemia reperfusion injury; FXR: Farnesoid X receptor. (Continuous line in case of an
increased/stimulatory effect; dashed line in case of a decreased/inhibitory effect.)
doi:10.1371/journal.pone.0169331.g007
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In our rodent model of extreme intestinal IRI (60 min of ischemia, followed by 60 min of
reperfusion), the mucosal epithelial integrity was severely breached, both structurally and
functionally. This was corroborated by high mortality (90% at 7 days), histopathological injury
(quantified by the Park-Chiu score and villus length), elevated intestine-specific (I-FABP)
injury markers [17,18], increased permeability with subsequent raised endotoxin-levels and a
protracted production of pro-inflammatory cytokines. We confirmed an association between
these detrimental events and a defective intestinal FXR pathway, which has been acknowl-
edged in models of IBD and cirrhosis as enteroprotective, both in terms of maintaining struc-
tural integrity and counter-regulating excessive local inflammatory events [8–10,13,34,36].
This apparent association was put to the test by pretreating animals with OCA, an oral FXR-
agonist, prior to induction of IRI, which not only protected against IRI-mediated epithelial cell
loss (and thus preservation of mucosal integrity and function) but also blocked endotoxin
translocation and an overzealous pro-inflammatory cascade leading to multiple organ failure
and death (Fig 7).
The precise mechanisms by which FXR is deactivated during IRI is still unclear but previ-
ous work suggests that this might be due to the elicited intestinal inflammation following pri-
mary injury, probably via NF-κB-dependent tethering of FXR [10,35,36]. Therefore, FXR not
only inhibits inflammation, but is also targeted by the inflammatory response itself (Fig 7).
This could explain a vicious cycle where reduced FXR activity results in protracted inflamma-
tion and damage both directly and indirectly [36]. The latter is of importance since tight junc-
tion-mediated regulation of paracellular intestinal permeability is highly regulated by local
expression of pro-inflammatory cytokines [9,46]. As seen in our model, the breakdown in bar-
rier function and increased inflammation resulted in a pronounced interstitial edema by
which bacterial products (like endotoxin) and neutrophils could infiltrate the subepithelial
space and eventually translocate. It is known that both contribute to epithelial permeability in
IBD [5,42,43].
Recently, Vavassori et al. (10) noticed that FXR activation represses the expression of toll-
like receptor-4 regulated genes, including NF-κB mediated pro-inflammatory cytokines (IL-1-
β, TNF-α, IFN-γ, cyclooxygenase-1 and 2) and chemokines, effects which were lost in FXR-
knockout mice. Also Gadaleta et al. [8] showed that administration of the FXR-agonist OCA
decreased intestinal inflammatory cytokine production (IL-1-β, IL-6) in a murine model of
IBD. In line with these findings, we observed in our intestinal IRI-model that maintained bar-
rier function after pretreatment with OCA was associated with decreased production of pro-
inflammatory cytokines such as IL-6, IL-1-β and IFN-γ. Interestingly, FXR agonism did not
influence anti-inflammatory cytokine expression in our IRI-model.
A final role of FXR in IRI is its potential effect on apoptosis and autophagy. Although per-
meability defects could conceivably be due to the marked intestinal epithelial cell apoptosis
that occurs during the intense inflammatory process, numerous studies have shown that epi-
thelial cell apoptosis alone does not entirely account for permeability deficits [37]. Although
FXR agonism alleviated intestinal IRI-related increase in apoptosis in our model, cleaved cas-
pase-3 comparison between the IR group and OCA-pretreated group did not reach signifi-
cance. The latter is consistent with the study by Inagaki et al. [13] who showed that FXR
activation blocked the inflammatory changes, without affecting programmed cell death.
Autophagy was hampered after IRI, as evidenced by an accumulation of LC3-I. LC3-I nor-
mally needs to convert into LC3-II by lipidation for a normal autophagic flux. Interestingly,
FXR activation reduced LC3 transcription, thereby alleviating this inhibition of autophagy. As
such, by regulating the input of LC3 molecules through activation of FXR, the autophagic flux
during IRI is balanced. This is important since autophagy’s self-recycling properties are crucial
for balancing sources of energy at critical times in development and in response to stress. It is
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mostly considered a cell survival mechanism, that -in addition to removing organelles, ribo-
somes, etc. . .- also promotes cellular senescence and cell surface antigen presentation, protects
against genome instability and prevents necrosis, features that all contribute to IRI [47,48].
The potential role of FXR in autophagy was recently described by Williams et al. [14] who
revealed a novel regulating function of FXR in transcription of SQSTM1, which encodes for
p62 protein. p62 plays an important role in maintaining cellular homeostasis through selective
autophagy and activating signal transduction pathways, such as NF-κB. Interestingly, they also
showed in mice that FXR agonism induced mRNA and protein expression of p62 in the ileum
[14]. In contrast, we showed that in a model of severe injury like intestinal IRI, FXR agonism
suppressed expression of p62 mRNA. Accordingly, it was recently shown in a model of fasted
mice that pharmacological activation of FXR repressed many autophagy genes by disrupting
the CREB-CRCT2 complex that under normal conditions upregulates autophagy [15]. These
data showed that by limiting gene expression, in a model of injury, FXR activation prevents
further accumulation of autophagic proteins (such as LC3-I) inhibiting its subsequent poten-
tial detrimental effects.
Conclusions
Our findings reveal a central role for FXR in intestinal IRI. Pretreatment with an FXR-agonist
OCA improves survival, preserves mucosal integrity, prevents bacterial translocation, limits
pro-inflammatory cytokine release and alleviates inhibition of autophagy. Altogether, these
results of OCA pretreatment strongly suggest that activation of FXR is a promising strategy to
prevent the deleterious effects of various conditions associated with occlusive and non-occlu-
sive intestinal ischemia. Future studies will reveal if the same findings can be obtained if OCA
is administered during the episode of ischemia.
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